IL326201A - 3-(4-cyclo-propoxybenzyl)-1-(2,4-difluorobenzyl)-1 -(1-methylpiperidin-4-yl)urea for use in the treatment of diseases associated with the serotonin-receptor 5-ht - Google Patents

3-(4-cyclo-propoxybenzyl)-1-(2,4-difluorobenzyl)-1 -(1-methylpiperidin-4-yl)urea for use in the treatment of diseases associated with the serotonin-receptor 5-ht

Info

Publication number
IL326201A
IL326201A IL326201A IL32620126A IL326201A IL 326201 A IL326201 A IL 326201A IL 326201 A IL326201 A IL 326201A IL 32620126 A IL32620126 A IL 32620126A IL 326201 A IL326201 A IL 326201A
Authority
IL
Israel
Prior art keywords
propoxybenzyl
difluorobenzyl
methylpiperidin
serotonin
cyclo
Prior art date
Application number
IL326201A
Other languages
Hebrew (he)
Original Assignee
Acadia Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acadia Pharm Inc filed Critical Acadia Pharm Inc
Publication of IL326201A publication Critical patent/IL326201A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL326201A 2023-08-02 2024-08-01 3-(4-cyclo-propoxybenzyl)-1-(2,4-difluorobenzyl)-1 -(1-methylpiperidin-4-yl)urea for use in the treatment of diseases associated with the serotonin-receptor 5-ht IL326201A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202363530291P 2023-08-02 2023-08-02
US202463554437P 2024-02-16 2024-02-16
PCT/US2024/040491 WO2025029990A1 (en) 2023-08-02 2024-08-01 3-(4-cyclo-propoxybenzyl)-1-(2,4-difluorobenzyl)-1 -(1-methylpiperidin-4-yl)urea for use in the treatment of diseases associated with the serotonin-receptor 5-ht

Publications (1)

Publication Number Publication Date
IL326201A true IL326201A (en) 2026-03-01

Family

ID=92543465

Family Applications (1)

Application Number Title Priority Date Filing Date
IL326201A IL326201A (en) 2023-08-02 2024-08-01 3-(4-cyclo-propoxybenzyl)-1-(2,4-difluorobenzyl)-1 -(1-methylpiperidin-4-yl)urea for use in the treatment of diseases associated with the serotonin-receptor 5-ht

Country Status (5)

Country Link
KR (1) KR20260048603A (en)
AU (1) AU2024317004A1 (en)
IL (1) IL326201A (en)
MX (1) MX2026001167A (en)
WO (1) WO2025029990A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI703130B (en) * 2014-03-07 2020-09-01 瑞士商赫爾辛保健股份有限公司 P-substituted asymmetric ureas and medical uses thereof
MX2020001757A (en) 2017-08-21 2020-09-07 Acadia Pharm Inc COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES.

Also Published As

Publication number Publication date
AU2024317004A1 (en) 2026-02-12
MX2026001167A (en) 2026-03-02
WO2025029990A1 (en) 2025-02-06
KR20260048603A (en) 2026-04-10

Similar Documents

Publication Publication Date Title
WO2021203103A3 (en) Ace2 receptor polymorphisms and varying susceptibility to sars-cov-2, methods for diagnosis and treatment
PH12012500809A1 (en) Methods and compositions for treating cancer
SG11202011872QA (en) 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases
PH12020551578A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
MX2021010058A (en) Topical rapamycin formulations and their use in treating facial angiofibromas and other skin disorders.
EP4497474A3 (en) Methods of treating rheumatic diseases using trimetazidine-based compounds
MX2020008680A (en) Combination therapy with apilimod and glutamatergic agents.
ATE453642T1 (en) SUBSTITUTED PHENYLAMINOPYRIMIDINES
MXPA05013733A (en) 2-aminobenzothiazoles as cb1 receptor inverse agonists.
PH12022551359A1 (en) Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases
WO2018060463A3 (en) Treatment of prostate cancer
NO20082923L (en) Use of a CB1 antagonist to treat side effects and negative symptoms of schizophrenia
MX2024008100A (en) Novel functionalized lactams as modulators of the 5-hydroxytryptamine receptor 7 and their method of use.
MX2020010879A (en) Bicyclic carboxamides and methods of use thereof.
MY192494A (en) Vaginal composition and use thereof
PH12020551573A1 (en) Pharmaceutical compositions for inhibiting inflammatory cytokines
WO2019103658A3 (en) 1,4-benzodiazapin-2-one derivatives and use thereof
JOP20210245A1 (en) Methods of Treating AL Amyloidosis
NZ811397A (en) Liquid tasimelteon formulations and methods of use thereof
CA3264923A1 (en) Composition for use in the treatment of fabry disease
CL2009000491A1 (en) Compounds derived from substituted 3- (4- (2-oxoindole) -piperidin) -pyrrolidines and 3- (4-benzo [b] imidazole) -piperidin) -pyrrolidines preparation process; pharmaceutical composition; intermediate compounds; Useful in the treatment of pain therapy, diseases such as Alzheimer's, anxiety, depression and glaucoma.
ATE478856T1 (en) SPIROBENZODIOXOLS AND THEIR USE AS CB1 ANTAGONISTS
NO20071704L (en) Prostaglandin derivatives for the treatment of gastrointestinal disorder
MXPA05003264A (en) 3,4-disubstituted pyrroles and their for use in treating inflammatory diseases.
DE602006017574D1 (en) USE AS PROTEIN KINASE INHIBITORS BENZIMIDAZOLE